Zobrazeno 1 - 10
of 370
pro vyhledávání: '"Coates LC"'
Autor:
Merola, JF, Landewé, R, McInnes, IB, Mease, PJ, Ritchlin, CT, Tanaka, Y, Asahina, A, Behrens, F, Gladman, DD, Gossec, L, Gottlieb, AB, Thaçi, D, Warren, RB, Ink, B, Assudani, D, Bajracharya, R, Shende, V, Coarse, J, Coates, LC
Publikováno v:
The Lancet, 401(10370), 38-48. Elsevier Limited
Background: Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F and IL-17A. This study compared the efficacy and safety of bimekizumab with placebo over 16 weeks in patients with active psoriatic arthritis and pre
Autor:
Ritchlin, CT, Coates, LC, McInnes, IB, Mease, PJ, Merola, JF, Tanaka, Y, Asahina, A, Gossec, L, Gottlieb, AB, Warren, RB, Ink, B, Bajracharya, R, Shende, V, Coarse, J, Landewé, R
Objectives: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17F in addition to IL‑17A. BKZ treatment has demonstrated superior efficacy versus placebo (PBO) at Week 16 in biologic disease‑modifying ant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1064::0ae8f298a66cfb33a4fb1de689e01e8c
https://ora.ox.ac.uk/objects/uuid:24f30bf1-7136-47c4-8f1d-af2f12c9bbad
https://ora.ox.ac.uk/objects/uuid:24f30bf1-7136-47c4-8f1d-af2f12c9bbad
Autor:
Ng, B, Jadon, D, Adebajo, A, Ayan, G, Callis Duffin, K, Chandran, V, Coates, LC, D’Agostino, MA, de Vlam, K, Deodhar, A, Eder, L, Garg, A, Gladman, DD, Goel, N, Gottlieb, A, Husni, ME, Katz, A, Kavanaugh, A, Lubrano, E, Mease, P, Merola, J, Nash, P, Ogdie, A, Pennington, S, Perez-Chada, LM, Proft, F, Rosen, CF, Savage, L, Goldenstein-Schainberg, C, Siebert, S, Soriano, E, Steinkoenig, I, Tillett, W, Armstrong, A, FitzGerald, O
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1064::96a2a3e87422fd4f0c5f57160ef207b2
https://ora.ox.ac.uk/objects/uuid:5163cd37-c34d-44a9-afdd-a352d54bd150
https://ora.ox.ac.uk/objects/uuid:5163cd37-c34d-44a9-afdd-a352d54bd150
Autor:
Leung, Y-Y, Tillett, W, de Wit, M, Orbai, A-M, Coates, LC, FitzGerald, O, Helliwell, PS, Strand, V, Mease, P, Goel, N, Christensen, R, Merola, JF, Lindsay, C, Ogdie, A, Gossec, L, Gladman, DD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1064::d2ea35dfb7c75a9c914694d7fa84794e
https://ora.ox.ac.uk/objects/uuid:8140d0a2-c340-4be9-8f90-b05ec031ebb4
https://ora.ox.ac.uk/objects/uuid:8140d0a2-c340-4be9-8f90-b05ec031ebb4
At the 2022 GRAPPA annual meeting, the recently published new GRAPPA recommendations were presented and their unique characteristics highlighted, including their truly international approach, the inclusion of patient views from the very beginning, th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1064::f3186448ed2d743455192d2bb7996ee4
https://ora.ox.ac.uk/objects/uuid:f4145d3a-4f46-4dc6-afce-b6a62fc26685
https://ora.ox.ac.uk/objects/uuid:f4145d3a-4f46-4dc6-afce-b6a62fc26685
Autor:
Hailey, LH, Amarnani, R, Bundy, C, McGagh, D, James, L, Kirtley, S, O'Sullivan, D, Steinkoenig, I, Suribhatla, R, Vivekanantham, A, Coates, LC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1064::7f3991f76de0e0efa12992a8af2c3e33
https://ora.ox.ac.uk/objects/uuid:4093adaf-66fe-4ba9-b987-b5a559da7744
https://ora.ox.ac.uk/objects/uuid:4093adaf-66fe-4ba9-b987-b5a559da7744
Autor:
Baraliakos, X, Ranza, R, Östör, A, Ciccia, F, Coates, LC, Rednic, S, Walsh, JA, Douglas, K, Gao, T, Kato, K, Song, I-H, Ganz, F, Deodhar, A
Publikováno v:
Arthritis Research & Therapy. 25
Background The objective of this post-hoc analysis was to assess the efficacy and safety of upadacitinib in psoriatic arthritis (PsA) patients with axial involvement. Methods Post-hoc analysis of SELECT-PsA 1 and SELECT-PsA 2 in patients randomized t
Publikováno v:
Rheumatology and Therapy. 9:803-821
Objective: This systematic literature review aimed to identify and summarise real-world observational studies reporting the type, prevalence and/or severity of residual symptoms and disease in adults with psoriatic arthritis (PsA) who have received t
Autor:
Strand, V, Kaeley, GS, Bergman, MJ, Gladman, DD, Coates, LC, Sherif, B, Hur, P, Parikh, B, Gilloteau, I, Mease, PJ
Publikováno v:
The Lancet Rheumatology. 4:e208-e219
Background: The phase 3 FUTURE 5 trial (NCT02404350) showed the clinical and radiographical efficacy of secukinumab in patients with psoriatic arthritis. This analysis aimed to assess the effect of secukinumab on patient-reported outcomes (PROs). Met